DividendApril 29, 2026

Dividend Win Wednesday: 7.4% FCF Yields, 55% Insider Buying, and FDA Priority Review

Top 5 Pixie Picks

This Week's Setup

FCF yields above 4% plus payout ratios below 65% flag companies with cash flow headroom, and this week the screen is stacked with pharma, energy, and defense names doing both while trading at 10–18% drawdowns from 52-week highs.

NVS, BIIB, GILD, and MRK all pair 4.6–7.4% FCF yields with sub-50% payout ratios; NEM and COP post 6.2–4.8% FCF yields while insiders add six-figure share blocks across gold and energy.

The S&P 500 CAPE (Shiller) sits at 38.9, historically elevated territory that rewards companies delivering cash now rather than promises later, and the Fear & Greed Index at 64 keeps the macro backdrop constructive without euphoria.

Quick Scan

#	Ticker	One-line thesis
1	NVS	5.5% FCF yield with 20 P/E and 19.7% ROIC
2	NEM	Gold miner at 14 P/E, 6.2% FCF, analysts see 30% upside
3	BIIB	7.4% FCF yield, 55% insider buying, zero dividend payout
4	GD	Defense contractor with 4.7% FCF yield, 26% analyst upside
5	COP	Energy at 20 P/E, 4.8% FCF yield, 11.9% upside
6	GILD	5.9% FCF yield, HIV NDA priority review, 22.8% upside
7	MRK	4.6% FCF yield, 15 P/E, 18% upside target
8	XOM	Energy with 3.8% FCF yield, insider buying, 10% upside

The 8 Names

1. Novartis AG (NVS)

Dividend yield: 3.3% | Payout ratio: 64.7% | 52w drawdown: 15.1%

NVS posts 5.5% FCF yield against a 3.3% dividend, leaving 2.2 percentage points of cash flow margin for reinvestment or buybacks, and the 19.7% ROIC on a 20.3 P/E makes this setup stand out among large-cap pharma. Gross margin of 75.8% and interest coverage at 15.3× flag operational strength while the stock sits 15% off highs.

Revenue growth of 9.6% year-over-year is solid but not explosive, and the 1.02 net debt to EBITDA ratio signals leverage that is manageable but not negligible in a rate-sensitive environment.

Analyst consensus at $153.26 implies only 5.8% upside from $144.81, the narrowest target margin in this screen; if the rerating doesn't materialize, the dividend and FCF yield are the only drivers here.

2. Newmont Corporation (NEM)

Dividend yield: 1.0% | Payout ratio: 15.7% | 52w drawdown: 18.7%

NEM delivers 6.2% FCF yield at a 14.2 P/E while paying out only 15.7% of earnings, the widest payout cover in this screen, and the 29.9% ROIC plus negative net debt to EBITDA of -0.20 signal a balance sheet with zero refinancing risk. Revenue growth of 21.3% year-over-year and 50.5× interest coverage make this the cleanest cash flow setup among gold miners.

Director Peter Toth filed a Form 4 on April 3, 2026, and insider net share purchases total 8,092 shares over six months with 2.3% of insiders adding to positions; analysts see 30.4% upside to $143.01 from $109.64, the highest target lift in this screen.

The 1.0% dividend yield is the lowest on this list; the setup here is FCF yield and capital appreciation, not income today.

3. Biogen Inc. (BIIB)

Dividend yield: 0.0% | Payout ratio: 0.0% | 52w drawdown: 10.0%

BIIB posts 7.4% FCF yield with zero dividend payout, routing all free cash into share repurchases and pipeline investment, and the 20.7 P/E against 75.7% gross margin flags pricing power in a specialty pharma business. The company topped Q1 earnings and revenue estimates, and analysts target $212.36 from $182.23, a 16.5% upside.

Insider activity over six months shows 55.3% of filings are buys versus 2.2% sells, with net purchases of 83,964 shares; Sean Godbout filed a Form 4 on April 3, 2026. The 7.65 insider score is the second-highest in this screen after XOM.

The 6.8% ROIC is the weakest in this list, and net debt to EBITDA of 0.79 is the highest among pharma names here; revenue growth of 2.2% year-over-year signals a business grinding for momentum rather than accelerating.

4. General Dynamics Corporation (GD)

Dividend yield: 2.0% | Payout ratio: 39.2% | 52w drawdown: 15.6%

GD pairs 4.7% FCF yield with a 39.2% payout ratio and 10.1% revenue growth year-over-year, the second-fastest top-line expansion in this screen behind NEM, and the Q1 earnings beat lifted the stock while Lockheed stumbled. Analysts see 26.0% upside to $393.07 from $311.88, the second-highest target lift after NEM.

Longview Asset Management filed a Form 4 on April 16, 2026, and insider net share purchases total 192,340 shares over six months with 21.9% of filings as buys versus 6.2% sells; the $6 million insider add flags conviction among institutional holders.

The five-year dividend growth rate is -7.9%, signaling prior capital allocation stress, and the 1.18 net debt to EBITDA ratio is the highest in this screen after XOM among defense and industrial names.

5. ConocoPhillips (COP)

Dividend yield: 2.7% | Payout ratio: 51.3% | 52w drawdown: 8.5%

COP delivers 4.8% FCF yield at 19.6 P/E with 13.4% ROIC and 7.7% revenue growth, and Morgan Stanley raised its price target to $149 from $108 while Goldman lifted Brent crude forecasts to $90, setting a macro tailwind for energy FCF. Interest coverage of 11.3× and net debt to EBITDA of 0.72 signal balance sheet flexibility for buybacks and dividend raises.

Three insiders filed Form 4s between April 23 and April 23, 2026: Silvina Vatnick, Ricardo Jaramillo Mejia, and Luis Fernando Restrepo Echavarria, with net purchases totaling 265,981 shares over six months; insider buy percentage of 1.18% versus 0.97% sells flags alignment at the executive level.

The 8.5% drawdown is the shallowest in this screen, meaning the entry discount is smaller than NVS, NEM, GILD, or GD; the setup here is momentum and analyst upgrades, not deep value.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.5% | Payout ratio: 47.8% | 52w drawdown: 18.0%

GILD posts 5.9% FCF yield at 19.0 P/E with 22.1% ROIC and 78.8% gross margin, the second-highest in this screen after NVS among pharma names, and the 47.8% payout ratio leaves room for dividend growth while the stock trades 18% off highs. Analysts target $158.36 from $128.97, a 22.8% upside.

⬡ The FDA granted priority review of the once-daily HIV treatment combining bictegravir plus lenacapavir, a New Drug Application milestone that shortens the approval timeline and sets a near-term binary catalyst for the stock; this is Gilead's most significant pipeline event in the quarter.

Johanna Mercier, Daniel Patrick O'Day, and Andrew D Dickinson filed Form 4s between March 30 and April 16, 2026, with net insider purchases of 266,263 shares over six months; 55.4% of filings are buys versus 34.7% sells.

7. Merck & Co., Inc. (MRK)

Dividend yield: 3.1% | Payout ratio: 46.0% | 52w drawdown: 12.2%

MRK delivers 4.6% FCF yield at 15.1 P/E with 20.0% ROIC and 74.8% gross margin, the cheapest valuation in this pharma cohort, and the 46.0% payout ratio plus 16.5× interest coverage flag balance sheet strength. Analysts see 18.0% upside to $129.74 from $109.91.

Revenue growth of 1.3% year-over-year is the slowest in this screen, and the net debt to EBITDA ratio of 1.24 is the highest among pharma names here; the setup is value and yield, not growth acceleration.

Thomas H Glocer, Mary Ellen Coe, and Christine E Seidman filed Form 4s on April 1, 2026, though insider net shares over six months are -19,199, signaling light selling pressure; the 21.1% insider buy percentage versus 22.3% sells flags a neutral insider stance rather than conviction buying.

8. Exxon Mobil Corporation (XOM)

Dividend yield: 2.7% | Payout ratio: 59.4% | 52w drawdown: 14.6%

XOM posts 3.8% FCF yield with 11.1% ROIC and 69.4× interest coverage, the highest debt serviceability in this screen, and the 59.4% payout ratio plus net debt to EBITDA of 0.67 signal room for dividend growth as energy prices stabilize. Analysts target $166.14 from $150.72, a 10.2% upside.

Insider net purchases total 1,061,250 shares over six months with 43.3% of filings as buys versus 0.8% sells, the widest buy-sell spread in this screen; the 7.12 insider score is the highest among all eight names and flags conviction at the executive and board level.

Revenue declined 4.5% year-over-year, the only negative top-line growth in this screen, and the 22.5 P/E is the highest valuation multiple among energy names here; the setup is cash return and balance sheet, not revenue momentum.

What to Watch

• GILD FDA decision on bictegravir-lenacapavir HIV NDA – Priority review status shortens the timeline; approval would validate the once-daily combo thesis and reset the HIV franchise growth trajectory.

• NEM quarterly earnings May 1 – Analysts expect continued revenue leverage from gold prices above $2,300/oz; guidance on capital allocation and dividend policy will frame the 30% upside case.

• COP and XOM Q1 energy earnings – Goldman's $90 Brent forecast and Morgan Stanley's upgraded energy targets set a macro tailwind; reported FCF will confirm whether buyback and dividend growth remain on track.

• GD defense budget commentary – The 26% analyst upside depends on sustained backlog growth; any guidance cut on federal procurement timelines would pressure the thesis.

Go Deeper

The dividend screener filters for companies with FCF yields above 4.5%, payout ratios below 65%, and balance sheet metrics that support sustained cash returns.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.